Quantcast

Latest Actinic keratosis Stories

2010-03-09 07:30:00

WILMINGTON, Mass., March 9 /PRNewswire-FirstCall/ -- DUSA Pharmaceuticals, Inc.(®) (Nasdaq: DUSA), a specialty pharmaceutical company focused primarily on the development and marketing of its Levulan(®) Photodynamic Therapy (PDT) technology platform for the prevention and treatment of dermatological skin conditions, announced that Bob Doman, President and Chief Executive Officer, will present a corporate overview at the Roth 22nd Annual OC Growth Stock...

2010-03-05 06:00:00

PARSIPPANY, N.J., March 5 /PRNewswire/ -- Specialty pharmaceutical company LEO Pharma today announced that findings from a Phase III study evaluating PEP005 (ingenol mebutate) Gel 0.05% to treat actinic keratosis (AK), a common pre-cursor to skin cancer, were presented at the 68th Annual Meeting of the American Academy of Dermatology (AAD) (Scientific Session Poster Discussion: P105). Results from REGION-I demonstrated treatment with PEP005 Gel once daily for 2 consecutive days (n=117) on...

2010-03-05 06:00:00

WILMINGTON, Mass., March 5 /PRNewswire-FirstCall/ -- DUSA Pharmaceuticals, Inc.(® )(NASDAQ GM: DUSA), a specialty pharmaceutical company focused on dermatology, will unveil an ergonomically enhanced BLU-U(®) Blue Light Photodynamic Therapy Illuminator at this year's American Academy of Dermatology (AAD) meeting in Miami, Florida, March 5-9. BLU-U, in conjunction with the Levulan(®) Kerastick(® )topical treatment, is an...

2010-02-26 05:30:00

WILMINGTON, Mass., Feb. 26 /PRNewswire/ -- DUSA Pharmaceuticals, Inc. (NASDAQ GM: DUSA) announces that its 2009 corporate highlights and year end financial results press release will be issued on Wednesday, March 3rd at 6:30 a.m. to be followed by a conference call at 8:30 a.m. Wednesday, March 3rd - 8:30 a.m. E.T. If calling from the U.S. or Canada use the following toll-free number: 800-647-4314 Password - DUSA For International callers use 502-498-8422 A replay of the call will be...

2010-02-02 07:30:00

WILMINGTON, Mass., Feb. 2 PRNewswire-FirstCall/ -- DUSA Pharmaceuticals, Inc.(®) (Nasdaq: DUSA), a specialty pharmaceutical company focused primarily on the development and marketing of its Levulan(®) Photodynamic Therapy (PDT) technology platform for the prevention and treatment of dermatological skin conditions, announced that Bob Doman, President and Chief Executive Officer, will present a corporate overview at the 12th Annual BIO CEO & Investor...

2010-02-01 08:38:00

BALLERUP, Denmark, Feb. 1 /PRNewswire-USNewswire/ -- LEO Pharma today announced that in a Phase III study, PEP005 (ingenol mebutate) Gel, the company's lead candidate for the topical treatment of actinic (solar) keratosis (AK) or pre-cancerous lesions, met its primary clinical endpoint of complete clearance of AK lesions in non-head locations. Findings from the REGION Ib study in body AK support results from the earlier REGION-I trial, a study evaluating PEP005 for the treatment of AK on...

2010-01-11 20:00:00

NEWPORT COAST, Calif., Jan. 11 /PRNewswire-FirstCall/ -- Solta Medical, Inc. (Nasdaq: SLTM) today announced the donation of a Fraxel re:store laser system to the Grossman Burn Foundation, the philanthropic arm of the Grossman Burn Center, a worldwide leader in innovative treatment and care for burn patients and their families. The Fraxel re:store system will be used to reduce the appearance of scarring caused by traumatic thermal damage. "Solta Medical is pleased to donate a Fraxel...

2009-11-10 05:30:00

WILMINGTON, Mass., Nov. 10 /PRNewswire/ -- The results of an independent investigator study just published in the online version of Dermatologic Surgery demonstrate that Levulan(®) Photodynamic Therapy (PDT) may reduce the rate of recurrence of squamous cell carcinomas (SCCs) in solid organ transplant recipients (SOTRs), a population with a high incidence of nonmelanoma skin cancer. This pilot study, which will also appear in the print version of the December issue of...

2009-11-06 14:26:00

WILMINGTON, Mass., Nov. 6 /PRNewswire-FirstCall/ -- DUSA Pharmaceuticals, Inc.(®) (Nasdaq GM: DUSA), a dermatology company that is developing and marketing Levulan(®) Photodynamic Therapy (PDT) and other products focused on patients with common skin conditions, announced that Bob Doman, President and Chief Executive Officer, will present a corporate overview at the Merriman Curhan Ford Investor Summit 2009 on Tuesday, November 10, 2009 at 10:00 a.m. ET at...

2009-11-03 05:30:00

WILMINGTON, Mass., Nov. 3 /PRNewswire-FirstCall/ -- DUSA Pharmaceuticals, Inc. (Nasdaq: DUSA) announces that its corporate highlights and third quarter financial results press release will be issued on Friday, November 6 at 6:30 a.m. to be followed by a conference call at 8:30 a.m. Friday, November 6 - 8:30 a.m. E.T. If calling from the US or Canada use the following toll-free number: 800.647.4314...


Word of the Day
bodacious
  • Remarkable; prodigious.
  • Audacious; gutsy.
  • Completely; extremely.
  • Audaciously; boldly.
  • Impressively great in size; enormous; extraordinary.
This word is probably from the dialectal 'boldacious,' a blend of 'bold' and 'audacious.'
Related